68 posts
FDA’s Tirzepatide OSA Approval Reshapes Peptide Therapy Demand and Supply
The FDA's tirzepatide OSA approval creates a new labeled use for a peptide drug, with implications for peptide therapy clinics, supply planning and research peptide suppliers.
Oct 23, 2026GLP-1 Addiction Repurposing: Mixed Trial Data Clouds Peptide Therapy Outlook
A review reports GLP-1 receptor agonists remain investigational for substance use disorders, with pooled trial data showing no significant reduction in alcohol consumption.
Oct 23, 2026GLP-1 Drug Standards: ANSI Maps ISO Framework Behind Safety and Quality
An ANSI overview maps the ISO and GLP standards behind GLP-1 drugs, from cleanrooms to injection pens, and flags what clinics and peptide suppliers must verify.
Oct 23, 2026GLP-1 Drugs Alone Fall Short, Doctors Say, as Peptide Clinics Weigh Lifestyle Care
Physicians say GLP-1 weight-loss drugs alone are not enough, urging exercise, nutrition, mental health support and monitored dosing as clinics reassess care models.
Oct 23, 2026Peptide Cleaning Validation Study Maps Worst-Case Residue for Shared GMP Equipment
A laboratory study identifies a C225HNO peptide API as the worst-case cleaning residue in shared equipment, offering a grouping template for peptide manufacturers.
Oct 22, 2026CagriSema Meta-Analysis: Dose-Specific GLP-1 Benefits Reshape Peptide Therapy Debate
A six-trial meta-analysis finds CagriSema lowers HbA1c and weight with dose-specific GI trade-offs, raising questions for peptide therapy clinics and suppliers.
Oct 22, 2026CordenPharma Pledges €80m to Expand Caponago Aseptic Fill & Finish for Peptide Injectables
CordenPharma will invest €80m in a new facility and aseptic fill & finish lines at Caponago, Italy, targeting peptide injectables, vials, cartridges and pens.
Oct 21, 2026Medical Disclaimer
Sanofi confirms intermittent U.S. supply of Lantus SoloStar pens as patients report refill failures. The device-level disruption offers lessons for peptide therapy supply chains.
Oct 20, 2026Terms of Service
A budget impact analysis in BMC Health Services Research estimates Saudi Arabia's 10-year GLP-1 obesity drug costs at SAR 10.96bn public and SAR 5.68bn private, rising to SAR 18.9bn under broad eligibility.
Oct 20, 2026What types of entities are included in PeptideSCM? It covers various categories of entities, such as factories, enterprises, logistics providers, clinics, pharmacies, laboratories, telemedicine websites, online vendors, gyms, and more.
PeptideSCM.net is a peptide supply-chain directory. It indexes the companies, facilities and organizations that move a peptide from a raw API drum to a patient — manufacturers, formulation plants, equipment makers, logistics providers, clinics, pharmacies, laboratories, telehealth platforms, online vendors and the service businesses around them. This guide lists every type of entity the directory […]
Oct 5, 2026Tirzepatide vs Liraglutide: Which Is Right for You?
Tirzepatide (once weekly) typically produces greater weight loss than liraglutide (daily) and is dual GIP/GLP-1 vs. GLP-1 only. Both are FDA-approved for diabetes and obesity. Tirzepatide is often preferred for maximum weight loss; liraglutide remains effective and may suit those who prefer daily do
Oct 2, 2026BPC-157 vs TB-500: Which Is Right for You?
BPC-157 and TB-500 are both prohibited for compounding in the US and have no FDA approval. They are marketed for tissue repair and recovery, with animal data but no completed human trials. Neither is a legal option for human use through US pharmacies.
Oct 2, 2026